Category Archives: Cf

This story is from March 2020

MINNEAPOLIS (WCCO) Dozens of businesses banded together to transform a nonprofit. It started with the Cystic Fibrosis Foundation.

A personal connection fostered the idea to give to those who always give to others. WCCO reveals the makeover and shares why the collective group wants to continue to pay it forward.

Step into the Cystic Fibrosis Foundation office in downtown Minneapolis and you know right where you are.

Our space before really could have been housed anything, any nonprofit, any organization. Now when you come in, it really speaks about our mission, executive director Joe Schwei said.

Thats to find a cure.

Whats really neat about the entire space is the continual messaging throughout whatever room youre in you have the continual reason youre here, Anton Newman with Fluid Interiors said.

Newman sparked the movement to transform the space once described as tragic.

Our collective that came together saw such a huge need in the nonprofit world theyre generally folks that are underserved from a capacity of their environment. They work so hard for us, Newman said.

And he recognized how a better space could propel the mission. Hes invested: his 3-year-old Bailey has CF. Dozens joined forces to donate time, labor, services and materials. The difference is dramatic.

We have the huddle room, we have the conference room. Theres areas around where weve got chairs grouped. In any kind of business were trying to strip down silos, so collaboration is key and weve got a space that really enables a lot more collaboration, Schwei said.

The makeover is designed to increase morale, productivity and retention. That can translate into dollars raised to fulfill the mission. But this is only the beginning for charities in Minnesota.

We would love to continue to affect one a year but what if it turns into 2, 3, 5 That would be amazing, Newman said.

The CF Foundation is grateful to be the first recipient of such a gift.

You start thinking about what a great legacy for these companies to have that they helped the nonprofit community of a major city like Minneapolis, Schwei said.

The CF Foundation staff looks forward to moving back into their newly transformed office space, when its safe to do so.

Nonprofits can apply online to become the next space selected. Click here to learn more. Heres more on the Minnesota Chapter of the Cystic Fibrosis Foundation.

Read more:

Group Of Businesses Help Give Cystic Fibrosis Foundations Office A Makeover - CBS Minnesota

CF and CFRP market research report brings to light key market dynamics of sector. The report gives correct insights on the current market scenario and future prospects of the CF and CFRP industry. It neatly describes historic data, present market trends, market environment, technological improvements, upcoming technologies and the technical progress in the related industry. Major market players, major collaborations, mergers & acquisitions are reviewed comprehensively in the CF and CFRP market report. Moreover, this market study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis. Market risks and entry barriers makes CF and CFRP industry attentive and help deciding further moves.

Download Sample (350 PDF) Report: To Know the Impact of COVID-19 on this Industry@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cf-cfrp-market

Global CF and CFRP Market Scenario

Global CF & CFRP market is expected to rise to an estimated value of USD 53.5 billion by 2026, registering a healthy CAGR in the forecast period of 2019-2026. The rise in the market value can be attributed to the focus on production of electricity from renewable sources and increase in demand for fuel-efficient vehicles.

Carbon fibers are widely used due to their superior properties like high chemical resistance, low weight & warm extension, compound resistance & rigidity and high stiffness. On the other hand, CFRP is a fiber-fortified plastic that contains carbon fibers. They are light weighted and tough. Both are used in sports merchandise, civil engineering, automotive and aviation industries that require rigid, lightweighted and high quality materials.

Market Drivers:

Market Restraints:

Key Insights in the report:

The 2020 Annual CF and CFRP Market offers:

100+ charts exploring and analysing the CF and CFRP Market from critical angles including retail forecasts, consumer demand, production and more

10+ profiles of top CF and CFRP Market producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Few of the major competitors currently working in the CF and CFRP market are Solvay SA, Hexcel Corporation, Gurit, Toray Industries Inc., TEIJIN LIMITED, SGL Group, Mitsubishi Chemical Holding Corporation, and Formosa Plastics Corporation among others.

Market Scope:

Moreover, two more major success factors of the credible CF and CFRP market report can be mentioned here which are market share analysis and key trend analysis. The research methodology employed in the report by DBMR research team is data triangulation which includes data mining, studying the impact of data variables on the market, and primary validation by industry experts. Being an outstanding and a comprehensive in nature, this report focuses on primary and secondary market drivers, market share, leading segments and geographical analysis. With the nice mixture of integrated approaches and latest technology, best results are achieved in the form of this CF and CFRP market research report.

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request DetailedTOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-cf-cfrp-market

The research provides answers to the following key questions:

The CF and CFRP Market segments and Market Data Break Down are illuminated below:

By Raw Material (Polyacrylonitrile Carbon Fibers, Pitch-Based Carbon Fiber, Rayon-Based Carbon Fiber)

Resin Type (Thermosetting CFRP, Thermoplastic CFRP)

Manufacturing Process (Lay-Up, Resin Transfer Molding, Compression Molding, Injection Molding, Filament Winding, Pultrusion)

End-User (Aerospace & Defence, Automotive, Wind Energy, Sporting Goods, Medical, Electronics, Marine)

Key Regions and Countries Studied in this report:

Have an Enquiry? Know more About Available customization in CF and CFRP Market Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cf-cfrp-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Originally posted here:

CF and CFRP Market Competitive Benchmarking And Regions Analysis By 2026: Solvay SA, Hexcel Corporation, Gurit, Toray Industries Inc., SGL Group - The...

CF Industries Holdings Inc. (CF) shares are trading at lower $38.17 and the avg recommendation for the stock is Moderate Buy, while the current analyst price target stands at $35.58.

To add more color to this target, the companys high over the last year is $48.88 and the low is $19.73. Over the last 52 weeks, CF is down -16.51% while the S&P 500 is up 15.47%. The catalyst for this interesting swing was the companys recent earnings report.

A Notable Earnings Report

In the last quarter, CF reported a profit of $83.0 million. CF Industries Holdings Inc. also saw revenues increase to $847.0 million. In addition, CF has free cash flow of $735.0 million as of 09-2020. The companys EBITDA came in at $252.0 million which compares well with its peers.

CF booked profit margins of 7.00%, its Return on Equity (ROE) is 10.10%, and its Return on Assets is 2.40%. All told, it is clear that, CF needs to be on your watchlist.

Find out when CF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. CF has a short ratio of 1.89 and outstanding shares of 213.90M.

Company Outlook

CF has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 3.83 million and more growth is possible in the weeks ahead. Traders will also note the companys earnings per share came in at 1.32. CF Industries Holdings Inc. CF also noted assets of $11.93 billion at the end of the last quarter. Investors should also keep an eye on sector updates as CF has historically followed its peers on positive news.

All told, CF Industries Holdings Inc. CF has strung together solid data and demonstrated underlying fundamentals. At its current valuation, CF represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

CF Industries Holdings Inc. CF is now commanding a market cap of 7.84B and a float of 212.81M. CF is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of CF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in CF, either long or short, and we have not been compensated for this article.

Post Views: 119

Continue reading here:

CF Industries Holdings Inc. (NYSE:CF) on the Path to Ruin - The Oracle Dispatch

Muhammad Mokaev is ready to take his career to the next level.

Mokaev (4-0) notched four pro wins in the span of four months as a bantamweight, and is now set to drop down to flyweight for his next bout as he sets his sights on his first pro title at 125 pounds.

Targeting a return in February, Mokaev told MMA Junkie he hopes to secure a No. 1 contender bout, then a shot at the Brave CF flyweight tournament winner.

I want (an) interim belt. Well, I dont know if Brave does this and then fight the winner of the tournament, Mokaev explained. Not like (a) fight for the belt, I want to fight the winner of the tournament. The biggest tournament in the world at the moment, so I want to fight the winner.

The Brave CF flyweight tournament includes the likes of former UFC fighters Jose Torres, Dustin Ortiz and Zach Makovsky, but Mokaev expects Torres (9-1-1) to emerge as the new flyweight champion.

With both men coming from similar amateur backgrounds, it would make for a great story. But, despite the gap in experience, Mokaev likes his chances against fellow former IMMAF amateur champion Torres.

He won two times the world championships, I won two times the world championships, but he was winning world championships when there was no Russia competing, when there was no Kazakhstan. There was America, U.K., some countries in Europe. Now, world championships are another level in IMMAF, so all countries are competing now.

Jose Torres isnt as motivated as I am. I follow him, we represent the same team, KHK, but hes my future opponent and when I saw him in Brave in October, I told him were gonna fight soon. Im hungrier than this guy. This guys lifestyle and my lifestyle are different.

In the quarterfinals of the flyweight tournament, Torres battled to a majority draw with Sean Santella at Brave CF 42 in September and the two are expected to rematch to determine who moves on to the semi-finals.

A fight with whoever ends up winning the tournament would mean a significant jump in competition for Mokaev, but he insists that hes ready and that this step up is necessary in order to achieve his goal of setting records for youngest champion.

Im already feeling strong, and I dont have much time, Mokaev said. I have three years to be the youngest UFC champion, the youngest Brave champion. If guys see me sparring with UFC fighters like featherweights and lightweights, they will understand that I can take some flyweights out and we have UFC fighters in the gym and my wrestling its not about strength, its about technique and understanding your energy level, when to spend and when to relax so I have enough experience at the moment.

Read more:

Muhammad Mokaev ready to step up, predicts Brave CF flyweight title bout with Jose Torres - MMA Junkie

Lets start up with the current stock price of CF Industries Holdings Inc. (CF), which is $35.82 to be very precise. The Stock rose vividly during the last session to $36.09 after opening rate of $34.03 while the lowest price it went was recorded $34.03 before closing at $33.50.

CF Industries Holdings Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $48.19 on 01/02/20, with the lowest value was $19.73 for the same time period, recorded on 03/18/20.

My Next COVID-19 Stock Alert Poised For Triple Digit Moves

Get Ready for my next COVID-19 stock idea.I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alerts first before the crowd.

>> Sign Up Now to Get Name & Ticker Symbolof Next Triple-Digit Gainer

Sponsored

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, CF Industries Holdings Inc. shares are logging -26.72% during the 52-week period from high price, and 81.55% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $19.73 and $48.88.

The companys shares, operating in the sector of Basic Materials managed to top a trading volume set approximately around 4578184 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CF Industries Holdings Inc. (CF) recorded performance in the market was -24.97%, having the revenues showcasing 7.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 7.35B, as it employees total of 3000 workers.

During the last month, 10 analysts gave the CF Industries Holdings Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 9 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 31.06, with a change in the price was noted +6.44. In a similar fashion, CF Industries Holdings Inc. posted a movement of +21.92% for the period of last 100 days, recording 2,491,618 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for CF is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.40.

Raw Stochastic average of CF Industries Holdings Inc. in the period of last 50 days is set at 97.50%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 97.50%. In the last 20 days, the companys Stochastic %K was 93.77% and its Stochastic %D was recorded 91.68%.

Considering, the past performance of CF Industries Holdings Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -24.97%. Additionally, trading for the stock in the period of the last six months notably improved by 19.52%, alongside a downfall of -20.31% for the period of the last 12 months. The shares increased approximately by 10.56% in the 7-day charts and went down by 29.88% in the period of the last 30 days. Common stock shares were driven by 7.15% during last recorded quarter.

Read more:

CF Industries Holdings Inc. (CF) is primed for evolution with the beta value of 1.14 - The InvestChronicle

Vertex might be the dominant force in cystic fibrosis, but there is still a small subset of patients in whom the companys drugs are not effective. Companies developing inhaled RNA-targeting projects, including Ionis, Arrowhead and Translate Bio, are hoping to reach the patients that Vertex cannot.

Potentially promising phase I data on Ioniss IONIS-ENAC-2.5Rx, reported yesterday, suggest this project as one to watch, though full results, due later this month, will be needed to gauge the assets chances properly. Meanwhile, phase I/II trials of Arrowhead and Translates candidates are set to read out next year.

CF is caused by mutations in the CFTR gene, which in turn leads to a defective and/or missing CFTR protein, which is vital for chloride transport. The result is the poor flow of salt and water into and out of cells in organs including the lung, and a build-up of a thick, sticky mucus.

Vertex has made strides with its CFTR modulators, but even its most advanced drug, the triplet Trikafta, can only treat 90% of the population.

The hope now is that new therapies could be effective in the remaining 10% of CF patients, who have a so-called nonsense mutation that essentially leads to no functional CFTR protein being produced.

Some of the projects, including those being developed by Arrowhead and Ionis, could also act synergistically with CFTR modulators.

Both assets are designed to reduce activity of the epithelial sodium channel (Enac) in the lung, as CTFR dysfunction also causes increased Enac activity, which is thought to contribute to airway dehydration. Ionis is using an antisense oligonucleotide, while Arrowhead is employing RNA interference.

Notably, Vertex already tried to inhibit Enac with small molecules licensed from Parion Sciences. But after the lead project, VX-371, fell short in clinical trials, Vertex returned rights to the smaller group at the beginning of this year.

According to Arrowhead, the development of inhaled small molecule Enac inhibitors was limited by on-target renal toxicity and short duration of action in the lung.

In August, that company started a phase I/II study of its candidate, ARO-ENaC, in up to 24 healthy volunteers and up to 30 CF patients. The primary endpoint is safety, but the trial will also evaluate various exploratory efficacy endpoints in CF patients including changes in lung clearance index and forced expiratory volume.

Ionis advances

Ionis is slightly further ahead, having reported somephase I data yesterday with IONIS-ENAC-2.5Rx. However, there is not much to go on: all the company has said is that in healthy volunteers given 75mg there was a mean 56% reduction in Enac mRNA expression and that this was statistically significant, withp<0.05.

The company also noted that, in mouse models, Enac mRNA reductions of 40% or more led to improvement in CF lung disease.

But it is data in humans that matter, and investors will be watching for full presentation of the results, due at the North American Cystic Fibrosis Conference, taking place virtually on October 21-23.

Stifel analysts raised several key questions, including whether any toxicity issues arose and whether the reduction in Enac expression, measured via bronchial cell brushings, was representative of what is happening across the lung.

Both projects could also have utility in other lung diseases like COPD; indeed, Ionis is already planning a phase II trial here.

Translating mRNA

Translate Bio, meanwhile, also hopes that its lead project, MRT5005, could be used in all CF patients, regardless of their mutation. But it is taking a different approach: the asset is designed to deliver mRNA encoding a fully functional CTFR protein to the lungs.

The group reported interim results from the single-ascending dose portion of its phase I/II trial in CF patients last year; data from the multiple-ascending dose portion had been due in 2020, but the trial was stopped earlier this year owing to the Covid-19 pandemic. Enrolment and dosing resumed last month, but Translate has not yet provided updated timelines for data.

For now, Translate is the lead mRNA player in CF, but there are a couple of other projects in preclinical development. Notably, Vertex and Moderna extended their research collaboration in CF in September. Given Vertexs success in the largerCF market, it might be too soon to count the company out completely.

Read this article:

Ionis joins the inhaled cystic fibrosis therapy race - Vantage

Dublin, Oct. 12, 2020 (GLOBE NEWSWIRE) -- The "CF & CFRP Market by Source (Virgin, Recycled), Precursor (PAN, Pitch, Rayon), Resin (Thermosetting, Thermoplastic), Manufacturing Process, End-use Industry, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global CF & CFRP market size is projected to grow from USD 17.5 billion in 2020 to USD 31.5 billion by 2025, at a CAGR of 12.4%

The CF & CFRP materials offer exceptional properties, such as low weight, stiffness, strength, tenacity, density, thermal & electrical conductivity, fatigue, and corrosion resistance. Owing to these outstanding properties, conventional materials, such as aluminum and steel, are less preferred in high-performance applications in various end-use industries, including aerospace & defense, wind energy, sporting goods, and among others. However, the global pandemic disease COVID-19 has forced the composite component manufacturers to shut down their operations partially, which is expected to decrease the demand for CF & CFRP in 2020.

The virgin carbon fiber segment of Carbon Fiber to be the fastest-growing segment.

The carbon fiber based on the source is segmented into virgin carbon fiber and recycled carbon fiber. Virgin is made from precursors such as PAN and pitch. These fibers find applications in various aerospace & defense, wind energy, sporting goods, and other industries. Virgin carbon fiber offers better thermal and mechanical properties than recycled carbon fiber. They are preferred over recycled carbon fiber in high-end aerospace applications.

PAN carbon fiber to be the faster-growing precursor type, in terms of value.

C PAN-based carbon fiber is a type of fiber produced by the carbonization of PAN precursor. Having high tensile strength and high elastic modulus, it is extensively used for structural material composites in aerospace & defense, automotive, and sporting goods industries. These properties are driving the use of PAN carbon fiber in various end-use industries.

Story continues

Owing to the COVID-19 pandemic, the new aircraft deliveries and wind energy installations are expected to reduce in 2020, which will result in reduced demand for PAN carbon fiber from these industries. The demand is expected to recover after 2020.

The thermoplastic segment to be the fastest-growing resin type, in terms of value, in the CF & CFRP market.

The application of thermoplastic polymer as a matrix material in CFRP composites has grown significantly in recent years. The thermoplastic resin is used with continuous fiber to create structural composite products. The main advantage of thermoplastic resin as matrix material is that, unlike thermoset resin, the composite formed can be reshaped and reformed. The composite formed is also easily recyclable. These factors are expected to drive the thermoplastic resin in the CFRP market during the forecast period.

The filament winding to be the fastest-growing manufacturing process, in terms of value, in the CF & CFRP market.

The filament winding process produces hollow or circular components such as compressed air tanks, high-pressure CO2 tanks & bottles, water softener systems, rescue air tanks, sailboat masts, CNG tanks, light poles, and other construction materials. This automated process is used to make highly engineered structures. The increased demand for CFRP from CNG and CHG tanks applications is expected to drive the filament winding CFRP market during the forecast period.

The COVID-19 pandemic has reduced the demand for CFRP tanks. Due to the lockdown situation, the demand for CFRP tanks has reduced from the gas transportation industry. The demand is expected to recover after the pandemic situation.

APAC is projected to be the fastest-growing CF & CFRP industry.

APAC is projected to be the fastest-growing CF & CFRP market during the forecast period. The region comprises countries such as Japan, China, South Korea, and Taiwan, having significant potential owing to the presence of established raw material suppliers, product manufacturers, and increasing new aircraft deliveries and wind energy installations in the region. There is a high demand for CF & CFRP from the wind energy, sporting goods, and aerospace industry in the region.

However, COVID-19 has negatively affected these industries in the APAC region. Japan, China, and Malaysia provide various components to aircraft manufacturers; China is the world's largest wind energy installer. The COVID-19 pandemic has resulted in less demand for the new aircraft and less wind energy installations, which are expected to reduce composite consumption in these countries in 2020.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights4.1 Attractive Opportunities in the CF & CFRP Market4.2 CFRP Market, by End-Use Industry and Region, 20194.3 Carbon Fiber Market, by Source4.4 Carbon Fiber Market, by Precursor Type4.5 CFRP Market, by Resin Type4.6 CFRP Market, by Manufacturing Process4.7 CFRP Market, by End-Use Industry4.8 CFRP Market, by Key Countries

5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Government Stimulus Packages for Aerospace and Other Industries for COVID-19 Crisis5.2.1.2 Increase in Demand for Fuel-Efficient Vehicles5.2.1.3 Increasing Demand from Wind Energy Industry5.2.2 Restraints5.2.2.1 Decrease in Number of Commercial Aircraft Deliveries5.2.2.2 Disruption in Supply Chain and Lower Production Capacity Utilization due to COVID-19 Pandemic5.2.2.3 High Cost of Carbon Fiber5.2.3 Opportunities5.2.3.1 Reduction in the Cost of Carbon Fiber5.2.3.2 Potential Opportunities in New Applications5.2.3.3 Growing Demand from Emerging Markets5.2.4 Challenges5.2.4.1 Maintaining Uninterrupted Supply Chain and Operating at Full Capacity5.2.4.2 Liquidity Crunch5.2.4.3 Development of Technology to Reduce Cycle Time5.3 Porter's Five Forces Analysis5.4 Value Chain Analysis5.5 Value Chain Analysis and Impact of COVID-195.6 Pricing Analysis5.7 Manuafturing Process Analysis5.8 Patent Analysis5.9 PESTEL Analysis5.10 Case Study

6 Macroeconomic Overview and Key Trends6.1 Introduction6.2 Trends and Forecast of GDP6.3 Impact of COVID-19 on Aerospace Industry6.3.1 Short-Term Strategies to Manage Cost Structure and Supply Chains6.3.2 New Opportunities6.4 Impact of COVID-19 on Automotive Industry6.4.1 Short-Term Strategies to Manage Cost Structure and Supply Chains6.4.2 Impact on Electric Vehicle (Ev) Demand due to Lower Oil Prices6.4.3 New Opportunities6.5 Impact of COVID-19 on Wind Energy Industry6.5.1 Short-Term Strategies to Manage Cost Structure and Supply Chains6.5.2 New Opportunities

7 Carbon Fiber Market, by Source7.1 Introduction7.2 Virgin Carbon Fiber7.2.1 Virgin Carbon Offers Better Thermal and Mechanical Properties Than Recycled Carbon Fiber7.3 Recycled Carbon Fiber7.3.1 Europe Leads the Demand for Recycled Carbon Fiber8 Carbon Fiber Market, by Precursor Type8.1 Introduction8.2 Polyacrylonitrile (Pan-Based) Carbon Fibers8.2.1 Pan-Based Carbon Fiber, by Tow Size8.2.1.1 Small-Tow (<24K)8.2.1.1.1 Small-Tow Carbon Fiber Finds Major Applications in Aerospace Industry8.2.1.2 Large-Tow (>24K)8.2.1.2.1 Wind Energy is Major Application of Large-Tow Carbon Fiber8.3 Pitch-Based Carbon Fiber8.4 Rayon-Based Carbon Fiber9 CFRP Market, by Resin Type9.1 Introduction9.2 Impact of COVID-19 on Resin Type9.3 Thermosetting CFRP9.3.1 Epoxy9.3.1.1 Epoxy Resin is Preferred in High-End Applications9.3.2 Vinyl Ester9.3.2.1 Vinyl Ester Resin Fin Applications in Transportation, Marine, and Pipe & Tank Industries9.3.3 Polyester9.3.3.1 Polyester is Cost-Competitive Resin9.3.4 Others9.4 Thermoplastic CFRP9.4.1 Polyetherethereketon (Peek)9.4.1.1 Peek Finds Extensive Use in Aerospace & Defense Applications9.4.2 Polyamide (Pa)9.4.2.1 Resistance to Wear, Heat, and Chemicals Supporting Growth of Polyamide Segment9.4.3 Polypropylene (Pp)9.4.3.1 Polypropylene-Based Thermoplastic Composites Have Huge Demand in Automotive Applications9.4.4 Others

10 CFRP Market, by Manufacturing Process10.1 Introduction10.2 COVID-19 Impact on Manufacturing Processes10.3 Lay-Up Process10.3.1 Aerospace & Defense End-Use Industry Drives the CFRP Market in Lay-Up Process10.4 Compression Molding Process10.4.1 Compression Molding Process Enables Short Cycle Time and a High Production Rate10.5 Resin Transfer Molding (Rtm) Process10.5.1 Rtm Process Used for Complex and Three Dimensional Components10.6 Filament Winding Process10.6.1 Pipe & Tank End-Use Industry Drives the CFRP Market in Filament Winding Process10.7 Injection Molding Process10.7.1 Automotive and Electrical & Electronics End-Use Industries Drives the CFRP Market in Injection Molding Process10.8 Pultrusion Process10.8.1 Wind Energy End-Use Industry is Largest Consumer of CFRP Pultruded Components10.9 Other Processes

11 CFRP Market, by End-Use Industry11.1 Introduction11.2 Aerospace & Defense11.2.1 Interior Parts11.2.1.1 Phenolic and Thermoplastic Composites Mainly Used in Aircraft Interior Structures11.2.2 Exterior Parts11.2.2.1 Fuselage, Wings, Rotor Blades, Tail Boom, and Radomes are Major Exterior Parts11.3 Wind Energy11.3.1 Wind Blades11.3.1.1 Carbon Fiber Widely Used for Making Spar Caps11.4 Automotive11.4.1 Interior Parts11.4.1.1 Seat Backs, Headliners, Package Trays, and Dashboards are Major Automotive Interior Parts11.4.2 Exterior Parts11.4.2.1 Exterior Parts are Major Applications in Automotive Industry11.5 Sporting Goods11.5.1 APAC Leads the Demand in Sporting Goods Industry11.6 Civil Engineering11.6.1 Restorations of Old Structures Driving the Use of Carbon Fiber11.7 Pipe & Tank11.7.1 Increase in Demand for Type Iv Cylinders Driving the CFRP Market11.8 Marine11.9 Electrical & Electronics11.9.1 APAC Leads Demand in Electrical & Electronics Segment11.10 Medical11.10.1 COVID-19 Pandemic Has Increased Demand for CFRP Materials in Medical Industry11.11 Other End-Use Industries12 CFRP Market, by Region12.1 Introduction12.2 North America12.4 APAC12.5 Latin America12.6 MEA (Middle East & Africa)

13 Competitive Landscape13.1 Introduction13.2 Market Share Analysis13.3 Market Evaluation Framework13.3.1 Expansion13.3.2 Agreement13.3.3 Acquisition13.3.4 Product Launch/Technology Launch13.3.5 Partnership13.3.6 Joint Venture13.3.7 Collaboration13.4 Revenue Analysis of Top Market Players, 201913.5 Company Evaluation Matrix13.5.1 Star13.5.2 Pervasive13.5.3 Participant13.5.4 Emerging Leaders13.6 Strength of Product Portfolio13.7 Business Strategy Excellence

14 Company Profiles14.1 Toray Industries Inc.14.2 Teijin Limited14.3 Mitsubishi Chemical Holdings Corporation14.4 Hexcel Corporation14.5 Solvay Group14.6 Sgl Group14.7 Formosa Plastics Corporation14.8 Hyosung14.9 Zhongfu Shenying Carbon Fiber Co., Ltd.14.10 Kureha Corporation14.11 Dowaksa14.12 Taekwang Industrial Co. Ltd.14.13 Jiangsu Hengshen Co., Ltd.14.14 Elg Carbon Fibre Ltd.14.15 Nippon Graphite Fiber Corporation14.16 Plasan Carbon Composites14.17 Kemrock Industries and Exports Ltd.14.18 Hindoostan Composite Solutions14.19 Crosby Composites14.20 Sigmatex Limited14.21 Zhongao Carbon14.22 Aeron Composite Pvt. Ltd.14.23 Weihai Tuozhan Fibers Co. Ltd.14.24 Cfk Valley Stade Recycling GmbH & Co. Kg14.25 Alabuga Fiber, LLC

15 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/k9jygd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:

CF & CFRP Market by Source, Precursor, Resin, Manufacturing Process, End-use Industry, and Region - Global Forecast to 2025 - Yahoo Finance

Vertex Pharmaceuticals (VRTX) has done well to help many patients in the cystic fibrosis (CF) community. The problem is that it has more patients to cover and to potentially improve treatment upon. Well, it has generated another partnership with Moderna (MRNA) for developing a potential gene editing therapy for the treatment of patients with cystic fibrosis. This is the second collaboration that provides an additional shot on goal. I believe this is a good move for Vertex as it looks to expand its presence in the CF space. It is imperative that Vertex moves to do this to address the patients that don't respond to its current therapies. Since Vertex's CFTR modulators only target those CF patients who produce the CFTR protein, about 10% don't respond to its drugs. A mode of action of developing a gene-edited therapy to address this issue is plausible. That's why I believe Vertex has the potential to eventually expand its market with this latest deal. There was another deal made with Moderna years earlier that is also progressing as well. This is why I think it's worth a look as a speculative investment.

Vertex Pharmaceuticals and Moderna Pharmaceuticals made an agreement, whereby Moderna would use its lipid nanoparticle (LNP) technology to develop gene-edited therapies to treat patients with cystic fibrosis. This is not a bad agreement at all. That's because Vertex is only paying $75 million upfront for this collaboration and then up to $380 million in additional milestone payments. This means Moderna will be responsible for starting off research activities of its LNP technologies to hopefully make something suitable to bring into the clinic in human testing. Vertex will help a little bit in the research by providing gene editing that is supposed to be incorporated into the LNPs being developed. This isn't the only deal that Vertex made to advance another potential CF drug. Back in 2016, Vertex made another deal, whereby Moderna would use its mRNA technology to deliver a gene-edited therapy for the treatment of patients with CF. This other deal was a multi-year agreement with a $20 million upfront payment and then $20 million in a Moderna convertible note that was to be converted to equity. From there, it would be about $275 million in milestone payments. The bottom line here is that there are two delivery approaches being made to deliver gene-edited therapies. Both LNP and mRNA have the potential to deliver the gene that CF patients need to develop the CFTR protein. As I noted in the beginning, despite several CFTR modulators that Vertex markets, there are 10% of patients who don't benefit at all from them. That means these gene-edited therapies may potentially allow these nonresponder patients to respond.

According to the 10-Q SEC Filing, Vertex Pharmaceuticals had cash, cash equivalents, and marketable securities of $5.5 billion as of June 30, 2020. It has a huge cash runway to fund its pipeline and meet its commitments. Not only that, but I don't foresee the need to also do a major cash raise. The reason why is that, if necessary, it can tap into a revolving credit facility that was done in 2019. That is, it can borrow up to $500 million according to this agreement. There are several benefits here with this agreement that are also a huge plus. This includes the ability to repay and reborrow without penalty. In addition, if it is ultimately needed, Vertex can ask the borrowing capacity to be increased by another $500 million. That would bring the possible borrowing power to $1 billion. Of course, that's only an option if Vertex really needs additional cash. However, Vertex is already producing substantial amounts of revenue. For its Q2 of 2020 earnings, it reported product revenues of $1.52 billion. That's substantial because that is a 62% increase compared to the same time period in 2019. That is not the only thing that should give investors confidence. Another positive development is that the company raised its full-year 2020 guidance higher. It originally was expecting full-year 2020 CF revenues of $5.3-5.6 billion. However, with increasing sales, it is now guiding its full-year 2020 CF revenues to be $5.7-5.9 billion.

The latest collaboration agreement between Vertex and Moderna is still risky. That's because this is only starting off in the research phase and where preclinical studies must be done first in animal testing. There is no guarantee that any candidate/s will make it to human clinical testing. If that happens, then it's possible that either the first or second collaboration agreement could be terminated. The good news is that there are two routes that will be attempted. One route is to use LNPs to deliver gene-edited CFTR protein and then the other one will use messenger RNA (mRNA) delivery technology instead. As long as one delivery tech candidate is successful, that will be good news for both patients and investors. On the flip side, as I have shown, Vertex is already producing substantial revenues from its currently marketed CFTR modulator drugs. A second risk could be an eventual slowdown in revenues because of the situation with Covid-19; however, that hasn't had a dramatic impact on sales as of yet.

Vertex Pharmaceuticals is a good buy based on its recent performance in sales. As noted above, sales year over year in Q2 2020 increased by 62% to $1.52 billion. Not only that but guidance was also increased as well. The recent deal with Moderna, plus the one made several years ago, has the potential to help the company expand its presence in the CF space. While many benefit from Vertex's CFTR modulator drugs currently available, there are many who still don't. Even then, the company is also expanding its current CFTR modulator therapies to other subpopulation of patients. For example, it recently received FDA approval of KALYDECO for use in CF patients who are aged 4 to less than 6 months that have at least 1 mutation in their CFTR gene. KALYDECO was already approved for use in the U.S. and EU in CF patients, however, that was for patients aged 6 months and older. This latest regulatory approval will allow Vertex to treat an additional group of patients it couldn't target before. For all these reasons, that's why I think Vertex is worth a look as a speculative buy.

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more from the original source:

Vertex Looks To Target 10% Of Cystic Fibrosis Population Not Yet Achieved By Its Current CFTR Modulators - Seeking Alpha

Leyland Trucks has completed the build of its 100,000th DAF CF / XF truck: a CF 530 FAT 64 drawbar chassis. The truck is part of a batch of four vehicles ordered by DAF Trucks Australia and is shortly to be exported, specd for the countrys fuel tanker market.

The state-of-the-art Leyland production facility has been producing DAF-branded commercial vehicles since the late eighties. Nowadays, Leyland Trucks builds the full range of market-leading DAF LF, CF and XF chassis in any configuration. Most of the CF and XF trucks that leave the assembly line are produced for Right Hand Drive markets, such as the UK and Australia. The plant recently received the coveted Queens Award for Enterprise 2020 for increasing exports by almost 50% over the last three years.

Landmark momentThis 100,000th CF and XF truck produced at the Leyland Assembly Plant is a hugely significant milestone for Leyland Trucks, said Leyland Trucks managing director Brennan Gourdie. There is a proud heritage of truck building in the UK and at Leyland, culminating with the production of the current line-up of DAF trucks today. 100,000 CF and XF chassis is a landmark moment representing an exceptional commitment from everyone here at Leyland and from the wider DAF organization world-wide.

SOURCE: DAF

Read more from the original source:

Leyland Trucks builds 100000th DAF CF / XF truck - Automotive World

Tampa Bay center fielder Kevin Kiermaier departed the Rays' American League Championship Series game against the Houston Astros on Tuesday with a bruised left hand, but he said after the game he is focused on getting back into the lineup.

Kiermaier got hurt when he was hit by a pitch in the sixth inning.

Appearing on the TBS postgame show with his hand and wrist wrapped, the Rays having just won 5-2 to take a 3-0 series lead in San Diego, Kiermaier was able to laugh about the injury.

"It feels like I got hit by 99 (mph) right in the wrist," he joked. "But we'll be OK. We got great trainers here. (I'll) try to recover as quick as I can, but it feels like how it should I feel like after getting hit by 99."

"Try to be hockey tough," he added.

Kiermaier yelled out loudly after the 0-2 fastball by Houston right-hander Enoli Paredes hit the hand. He was examined by trainers and initially stayed in the game and scored one of the runs in Tampa Bay's five-run inning.

But Kiermaier, a two-time Gold Glove winner, didn't take the field for the bottom of the sixth as he instead went to get X-rays. Hunter Renfroe, who pinch-hit during the sixth inning, stayed in the game in right field as Manuel Margot moved to center.

TBS soon reported that X-rays were negative.

Kiermaier was 0-for-2 with a strikeout before exiting. He is 2-for-9 in the series.

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free.Please support us by subscribing or making a contribution today.

Originally posted here:

Rays CF Kiermaier departs with hand injury | Sportsxchange - Rockdale Newton Citizen